Drugs / Proellex
Proellex
Trials 29
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT02141061 | May → Jun 2014 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01962805 | Oct → Dec 2013 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00881062 | Apr → May 2009 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00881608 | Feb → Aug 2009 | amenorrhea | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00741273 | Oct 2008 → May 2009 | liver disorder | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00749879 | Aug → Oct 2008 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00741468 | Jul → Sep 2008 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00620503 | Feb → Apr 2008 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00619385 | Feb → Sep 2008 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01067807 | Jun → Jul 2007 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01187043 | Aug 2010 → Mar 2012 | amenorrhea | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 215 trials · 2 met primary | ||||||
| Phase 2 | NCT02811159 | Jul 2016 → May 2017 | leiomyoma | Repros Therapeutics Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02301897 | Mar 2015 → Jun 2017 | uterine corpus leiomyoma | Repros Therapeutics Inc. | Completed | Met primary |
| Phase 2 | NCT02323646 | Feb 2015 → Apr 2017 | uterine benign neoplasm | Repros Therapeutics Inc. | Completed | Met primary |
| Phase 2 | NCT01961908 | Dec 2013 → Dec 2014 | endometriosis | Repros Therapeutics Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT01800422 | Jun 2013 → Jun 2021 | female breast carcinoma | Northwestern University | Unknown | No outcome recorded |
| Phase 2 | NCT01728454 | May 2013 → Mar 2017 | endometriosis | Repros Therapeutics Inc. | Completed | Mixed |
| Phase 2 | NCT01739621 | Sep 2012 → Apr 2014 | leiomyoma | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01631903 | Sep 2012 → Apr 2014 | uterine corpus leiomyoma | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01451424 | Feb → Dec 2012 | leiomyoma | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00958412 | Feb → Aug 2009 | endometriosis | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00958893 | Jun 2008 → Aug 2009 | leiomyoma | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00683917 | May 2008 → Aug 2009 | leiomyoma | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00556075 | Nov 2007 → May 2009 | endometriosis | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00958334 | Sep 2006 → Oct 2008 | leiomyoma | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00882258 | Mar 2006 → Mar 2007 | leiomyoma | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00785356 | Oct 2008 → Aug 2009 | anemia, leiomyoma | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00702702 | Jun 2008 → Aug 2009 | anemia, leiomyoma | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00874302 | — | uterine corpus leiomyoma | Repros Therapeutics Inc. | Withdrawn | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT00787618 Comparator | Oct 2008 → Jun 2009 | impaired renal function disease | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02314156 Comparator | Oct 2015 → Jan 2018 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, ductal breast carcinoma in situ, female breast carcinoma +1 | Northwestern University | Completed | No outcome recorded |
| Phase 3 | NCT01069120 Comparator | Apr → Aug 2009 | leiomyoma | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00853567 Comparator | Feb → Aug 2009 | uterine benign neoplasm | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00737282 Comparator | Oct 2008 → Aug 2009 | leiomyoma | Repros Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00735553 Comparator | Aug 2008 → Aug 2009 | leiomyoma | Repros Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Proellex | “Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200” NCT01739621 ↗ |
| Known as | CDB-4124 | “Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids” NCT00853567 ↗3“Selective Progesterone Receptor Modulator Proellex® (CDB-4124)” NCT00785356 ↗ “Selective Progesterone Receptor Modulator Proellex® (CDB-4124)” NCT00702702 ↗ “Proellex® (CDB-4124)” NCT00741273 ↗ |
| Known as | Telapristone Acetate | “Telapristone acetate, 1 vaginally inserted capsule, once a day, for 4 months” NCT01739621 ↗8“Proellex® (Telapristone Acetate)” NCT01631903 ↗ |
| Known as | telepristone acetate | “telepristone acetate 12 mg” NCT01631903 ↗ |
| Action | Inhibit | “suppress the effects of endogenous progesterone” NCT00881608 ↗ |
| Modality | Other / unclassified | “Selective Progesterone Receptor Modulator Proellex® (CDB-4124)” NCT00785356 ↗ |
| Route | Oral | “orally daily” NCT00735553 ↗ |